Kai Clarke

Dr. Kai Clarke

Biomedical Engineering, University of Connecticut Health, Farmington, Connecticut, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MHMarja Hurley
Marja Hurley
JCJ. Douglas Coffin
J. Douglas Coffin
TDThomas Doetschman
Thomas Doetschman
CVChristina Valera
Christina Valera
Kai ClarkeKai Clarke
Kai Clarke
LXLiping Xiao
Liping Xiao
We have used Basic Fibroblast Growth Factor (FGF2) transgenic mice as experimental models for human X-linked hypophosphatemia (XLH)-related degenerative osteoarthritis (OA) to investigate the pathogenesis of the disease and to test potential pharmacotherapies for treatment. This study tested the efficacy of BJG398, a small molecule fibroblast growth factor receptor tyrosine kinase (FGFRTK) inhibitor, to rescue the knee joint osteoarthritis phenotype in High Molecular Weight fibroblast growth factor 2 transgenic (HMWTgFGF2) mice. BJG398 was administered in vivo to 8-month-old female HMWTgFGF2 mice for six weeks. Histomorphometry, immunohistochemistry and micro-CT were used to examine the knee joints in BGJ398-treated and control mice. We assessed: Fibroblast Growth Factor 23 (FGF23) expression and FGFR1 activity; Matrix metalloproteinase 13 (MMP13) and Aggrecanase2 (ADAMTS5) expression; then signaling by SMAD1/5/8-pSMAD6, pERK1/2 and Runt-related transcription factor 2 (RUNX2). Using PrimePCR arrays, we identified a contributing role for major target genes in the TGFB/BMP2 signaling pathway that were regulated by BGJ398. BGJ398 inhibited HMWFGF2/FGF23-induced increase in bone morphogenic protein receptor-1, bone morphogenic protein-2 and 4 and Serine peptidase inhibitor, clade E, member 1. The results from Micro-CT and histology show BGJ398 treatment rescued the OA changes in subchondral bone and knee articular cartilage of HMWTgFGF2 mice. The gene expression and signal transduction results provide convincing evidence that HMWFGF2 generates OA through FGFRTK with characteristic downstream signaling that defines OA, namely: increased FGF23-FGFR1 activity with BMP-BMPR, activation of pSMAD1/5/8-RUNX2 and pERK signaling pathways, then upregulation of MMP13 and ADAMTS5 to degrade matrix. BGJ398 treatment effectively reversed these OA molecular phenotypes, providing further evidence that the OA generated by HMWFGF2 in the transgenic mice is FGFR-mediated and phenocopies the OA found in the Hyp mouse homolog of XLH with a spontaneous mutation in the Phex (phosphate regulating endopeptidase on the X chromosome) gene and human XLH-OA. Overall, the results obtained here explain how the pleotropic effects of FGF2 emanate from the different functions of HMW protein isoforms for cartilage and bone homeostasis, and the pathogenesis of XLH-degenerative osteoarthropathy. BGJ398 inhibits HMWFGF2-induced osteoarthritis via multiple mechanisms. These results provided important scientific evidence for the potential application of BGJ398 as a therapeutic agent for osteoarthritis in XLH.

2 November 2023 in Endocrinology
Verified
Journal Article
Closed access
PDF file
LXLiping Xiao
Liping Xiao
Kai ClarkeKai Clarke
Kai Clarke
MHMarja Hurley
Marja Hurley
We assessed the involvement of FGF23 in phosphaturia in sickle cell disease (SCD) mice. Control and SCD mice were treated with FGF23 neutralizing antibody (FGF23Ab) for 24 hours. Serum ferritin was significantly increased in SCD mice and was significantly reduced in female but not male SCD mice by FGF23Ab. FGF23Ab significantly reduced increased erythropoietin in SCD kidneys. Serum intact FGF23 (iFGF23) was significantly increased in SCD female mice and was markedly increased in SCD male mice, however, FGF23Ab significantly reduced iFGF23 in both genotypes and sexes. Serum carboxy-terminal-fragment FGF23 (cFGF23) was significantly reduced in SCD-IgG male mice and was markedly but not significantly reduced in SCD-IgG female mice. FGF23Ab significantly increased cFGF23 in both sexes and genotypes. Serum 1,25-dihydroxyvitamin D3 was significantly increased in SCD-IgG and was further significantly increased by FGF23Ab in both sexes and genotypes. Significantly increased BUN in SCD was not reduced by FGF23Ab. Urine phosphate/creatinine ratio was significantly increased in SCD in both sexes and was significantly reduced by FGF23Ab. Increased SCD kidney damage marker KIM1 was rescued, but sclerotic glomeruli, increased macrophages, and lymphocytes were not rescued by short-term FGF23Ab. FGF23Ab significantly reduced increased pFGFR1, αKlotho, pERK, pSGK1, pNHERF-1, pJAK3, and pSTAT3 in SCD kidneys. The sodium phosphate co-transporter NPT2a and sodium-dependent phosphate transporter PiT-2 proteins were significantly reduced in SCD kidneys and were increased by FGF23Ab. We conclude that increased FGF23/FGFR1/αKLOTHO signaling promotes phosphate wasting in SCD by downregulating NPT2a and PiT2 via modulation of multiple signaling pathways that could be rescued by FGF23Ab.

29 October 2021 in Macromolecular Bioscience
Verified
Journal Article
Closed access
PDF file
MSMahyar Sameti
Mahyar Sameti
Kai ClarkeKai Clarke
Kai Clarke
PDPrerona Dewan
Prerona Dewan
KWKenyatta S. Washington
Kenyatta S. Washington
STSomayeh Talebzadeh
Somayeh Talebzadeh
CBChris Bashur
Chris Bashur

20 June 2025 in Archives of Oral Biology
Verified
Journal Article
Open access
SKSobhan Katebifar
Sobhan Katebifar
Kai ClarkeKai Clarke
Kai Clarke
BRBradley S. Rosenberg
Bradley S. Rosenberg
MTMichael Truhlar
Michael Truhlar
ADAlix C. Deymier
Alix C. Deymier
This study investigates the structural and compositional features of the dentin-enamel junction in the osteogenesis imperfecta murine teeth, focusing on the effects of dentinogenesis imperfecta, sex, and tooth type. The study compares dentin-enamel junctions in molars and incisors, as these teeth experience different functions and growth patterns, using a multiscale approach that combines micro-computed tomography (micro-CT), Scanning Electron Microscopy (SEM), and Raman Spectroscopy techniques. The width of the mantle dentin is significantly reduced in dentinogenesis imperfecta-affected mice. Female mice show significantly larger gradients in mineral content and structural dentin-enamel junction than male mice. Molars have larger gradient widths compared to incisors. Molars exhibit higher dentin porosity and a smaller mantle dentin width compared to incisors. Dentinogenesis imperfecta causes a decrease in tubule diameter and an increase in the number of tubules, which may contribute to heightened tooth sensitivity in dentinogenesis imperfecta-affected mice. Females may have better resilience to stress and fractures, potentially explaining why dentinogenesis imperfecta might be diagnosed more frequently in males. Larger gradient widths in molars may help protect them due to their different functions and mechanical stresses.

3 July 2026 in Cells
Verified
Journal Article
Open access
PDF file
Kai ClarkeKai Clarke
Kai Clarke
WHWei He
Wei He
NMNikhil Menon
Nikhil Menon
Tannin SchmidtTannin Schmidt
Tannin Schmidt
PDPierre Deymier
Pierre Deymier
MHMarja Hurley
Marja Hurley
Sickle cell disease (SCD), the most common inherited blood disorder in the United States, affects approximately 100,000 individuals annually. A major complication of SCD is sickle cell bone disease, which results in substantial bone loss comparable to osteoporosis. Previous work showed that treatment with GBT1118, a sickle hemoglobin polymerization inhibitor, improved bone formation and reduced bone resorption in humanized SCD mice. However, its effects on bone material and mechanical properties were unknown. To address this, four-month-old control and SCD mice were fed vehicle or GBT1118 chow for two months. Hematocrit levels, significantly reduced in SCD mice of both sexes, were restored by GBT1118 treatment, confirming its efficacy in improving anemia. Raman spectroscopy revealed increased mineral-to-organic matrix ratios in SCD femurs of both sexes and elevated carbonate-to-phosphate ratios in males, none of which were altered by GBT1118. Mechanical testing showed decreases in ultimate stress and Young’s modulus in female SCD femurs, with no significant differences in males nor rescue by GBT1118. Thus, while GBT1118 improved hematological parameters, it failed to restore the impaired bone material properties observed in SCD mice, highlighting the need for additional therapeutic strategies to address bone fragility in sickle cell disease.